biotech / news / / Reuters
Pfizer sold nearly $6.4 billion of Vyndamax and related drugs in 2025.
Pfizer's Vyndamax patent protection in the U.S. is extended until June 1, 2031.
KEY POINTS
- Previously predicted revenue decline in 2029 for Vyndamax is now expected to be delayed until mid-2031.
- The patent settlements will smooth Pfizer’s late-2020s earnings, compensating for other key drug expirations.
- In 2025, Pfizer sold nearly $6.4 billion of Vyndamax and related ATTR-CM drugs.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →